# Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

> **NCT06650748** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Peking University** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer
- Early-stage Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT06650748
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-05-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650748, "Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06650748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*